New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
09:13 EDTBMRNBioMarin says change ups chance to hit cognition endpoint, says Janney Capital
Janney Capital noted that BioMarin's PEG-PAL study has been changed in terms of entry criteria, which will delay study results. However, the firm said management acknowledged that they think this change increases the chance of the study hitting the cognition endpoint, which Janney believes would strengthen the drug’s label and commercial outlook if it occurs. Janney has a Buy rating on BioMarin.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 8, 2014
07:15 EDTBMRNIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use